Critical Roles of IL-33/ST2 Pathway in Neurological Disorders

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 2018 Mar 7

PMID 29507527

Citations 17

Authors

Mohammad Faruq Abd Rachman Isnadi

Voon Kin Chin

Roslaini Abd Majid

Tze Yan Lee

Maizaton Atmadini Abdullah

Ramatu Bello Omenesa

Zaid Osamah Ibraheem

Rusliza Basir

Affiliations

Soon will be listed here.

Abstract

Interleukin-33 (IL-33) is an IL-1 family member, which exhibits both pro- and anti-inflammatory properties solely based on the type of the disease itself. Generally, IL-33 is expressed by both endothelial and epithelial cells and mediates its function based on the interaction with various receptors, mainly with ST2 variants. IL-33 is a potent inducer for the Th2 immune response which includes defence mechanism in brain diseases. Thus, in this paper, we review the biological features of IL-33 and the critical roles of IL-33/ST2 pathway in selected neurological disorders including Alzheimer's disease, multiple sclerosis, and malaria infection to discuss the involvement of IL-33/ST2 pathway during these brain diseases and its potential as future immunotherapeutic agents or for intervention purposes.

Citing Articles

Association between Atopic Dermatitis and Dementia: Evidence from Systematic Review, Meta-analysis, and Mendelian Randomization.

Gwak Y, Kim S, Woo C, Shin K, Son E, Kim J Acta Derm Venereol. 2025; 105:adv41321.

PMID: 39749391 PMC: 11697145. DOI: 10.2340/actadv.v105.41321.

Critical and diverse role of alarmin cytokines in parasitic infections.

Xing Z, Liu S, He X Front Cell Infect Microbiol. 2024; 14:1418500.

PMID: 39559705 PMC: 11570582. DOI: 10.3389/fcimb.2024.1418500.

IL-33/ST2 Axis: A Potential Therapeutic Target in Neurodegenerative Diseases.

Jia Z, Guo M, Ge X, Chen F, Lei P Biomolecules. 2023; 13(10).

PMID: 37892176 PMC: 10605306. DOI: 10.3390/biom13101494.

ASC- and caspase-1-deficient C57BL/6 mice do not develop demyelinating disease after infection with Theiler's murine encephalomyelitis virus.

Li D, Buhler M, Runft S, Gerold G, Marek K, Baumgartner W Sci Rep. 2023; 13(1):10960.

PMID: 37414913 PMC: 10326010. DOI: 10.1038/s41598-023-38152-3.

The IL-33/ST2 Pathway in Cerebral Malaria.

Glineur C, Leleu I, Pied S Int J Mol Sci. 2022; 23(21).

PMID: 36362246 PMC: 9658244. DOI: 10.3390/ijms232113457.

References

Carrillo M, Dean R, Nicolas F, Miller D, Berman R, Khachaturian Z . Revisiting the framework of the National Institute on Aging-Alzheimer's Association diagnostic criteria. Alzheimers Dement. 2013; 9(5):594-601. DOI: 10.1016/j.jalz.2013.05.1762. View

Demyanets S, Kaun C, Pentz R, Krychtiuk K, Rauscher S, Pfaffenberger S . Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. J Mol Cell Cardiol. 2013; 60:16-26. PMC: 3683148. DOI: 10.1016/j.yjmcc.2013.03.020. View

Garlanda C, Anders H, Mantovani A . TIR8/SIGIRR: an IL-1R/TLR family member with regulatory functions in inflammation and T cell polarization. Trends Immunol. 2009; 30(9):439-46. DOI: 10.1016/j.it.2009.06.001. View

Frohman E, Racke M, Raine C . Multiple sclerosis--the plaque and its pathogenesis. N Engl J Med. 2006; 354(9):942-55. DOI: 10.1056/NEJMra052130. View

Kornek B, Lassmann H . Neuropathology of multiple sclerosis-new concepts. Brain Res Bull. 2003; 61(3):321-6. DOI: 10.1016/s0361-9230(03)00095-9. View

De la Fuente M, Macdonald T, Hermoso M . The IL-33/ST2 axis: Role in health and disease. Cytokine Growth Factor Rev. 2015; 26(6):615-23. DOI: 10.1016/j.cytogfr.2015.07.017. View

Palmer G, Lipsky B, Smithgall M, Meininger D, Siu S, Talabot-Ayer D . The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine. 2008; 42(3):358-64. DOI: 10.1016/j.cyto.2008.03.008. View

Louten J, Rankin A, Li Y, Murphy E, Beaumont M, Moon C . Endogenous IL-33 enhances Th2 cytokine production and T-cell responses during allergic airway inflammation. Int Immunol. 2011; 23(5):307-15. DOI: 10.1093/intimm/dxr006. View

Kuchler A, Pollheimer J, Balogh J, Sponheim J, Manley L, Sorensen D . Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am J Pathol. 2008; 173(4):1229-42. PMC: 2543089. DOI: 10.2353/ajpath.2008.080014. View

10.

Iwahana H, Hayakawa M, Kuroiwa K, Tago K, Yanagisawa K, Noji S . Molecular cloning of the chicken ST2 gene and a novel variant form of the ST2 gene product, ST2LV. Biochim Biophys Acta. 2004; 1681(1):1-14. DOI: 10.1016/j.bbaexp.2004.08.013. View

11.

Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H . Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000; 47(6):707-17. DOI: 10.1002/1531-8249(200006)47:6<707::aid-ana3>3.0.co;2-q. View

12.

Liu X, Hammel M, He Y, Tainer J, Jeng U, Zhang L . Structural insights into the interaction of IL-33 with its receptors. Proc Natl Acad Sci U S A. 2013; 110(37):14918-23. PMC: 3773798. DOI: 10.1073/pnas.1308651110. View

13.

Lingel A, Weiss T, Niebuhr M, Pan B, Appleton B, Wiesmann C . Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors--insight into heterotrimeric IL-1 signaling complexes. Structure. 2009; 17(10):1398-410. PMC: 2766095. DOI: 10.1016/j.str.2009.08.009. View

14.

Li P, Ma H, Han D, Mou K . Interleukin-33 affects cytokine production by keratinocytes in vitiligo. Clin Exp Dermatol. 2014; 40(2):163-70. DOI: 10.1111/ced.12464. View

15.

Ali S, Huber M, Kollewe C, Bischoff S, Falk W, Martin M . IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci U S A. 2007; 104(47):18660-5. PMC: 2141833. DOI: 10.1073/pnas.0705939104. View

16.

Schiering C, Krausgruber T, Chomka A, Frohlich A, Adelmann K, Wohlfert E . The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature. 2014; 513(7519):564-568. PMC: 4339042. DOI: 10.1038/nature13577. View

17.

Martin M . Special aspects of interleukin-33 and the IL-33 receptor complex. Semin Immunol. 2013; 25(6):449-57. DOI: 10.1016/j.smim.2013.10.006. View

18.

Allan D, Fairlie-Clarke K, Elliott C, Schuh C, Barnett S, Lassmann H . Role of IL-33 and ST2 signalling pathway in multiple sclerosis: expression by oligodendrocytes and inhibition of myelination in central nervous system. Acta Neuropathol Commun. 2016; 4(1):75. PMC: 4960877. DOI: 10.1186/s40478-016-0344-1. View

19.

Yasuoka S, Kawanokuchi J, Parajuli B, Jin S, Doi Y, Noda M . Production and functions of IL-33 in the central nervous system. Brain Res. 2011; 1385:8-17. DOI: 10.1016/j.brainres.2011.02.045. View

20.

Yanagisawa K, Takagi T, Tsukamoto T, Tetsuka T, Tominaga S . Presence of a novel primary response gene ST2L, encoding a product highly similar to the interleukin 1 receptor type 1. FEBS Lett. 1993; 318(1):83-7. DOI: 10.1016/0014-5793(93)81333-u. View